Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
July 09, 2024 09:47 ET
|
Curium
Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
June 17, 2024 08:51 ET
|
Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
June 17, 2024 08:51 ET
|
Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
June 05, 2024 05:27 ET
|
Curium
Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
May 30, 2024 03:00 ET
|
Curium
first doses of PYLCLARI in France for prostate cancer patients
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
May 30, 2024 03:00 ET
|
Curium US LLC
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024 03:32 ET
|
Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs
May 06, 2024 04:25 ET
|
Curium
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
May 06, 2024 04:25 ET
|
Curium
Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
April 23, 2024 00:01 ET
|
Curium
patient enrollment in clinical trial